Lucentis (ranibizumab) / Roche, Novartis, Santen, China Medical System - LARVOL DELTA

Efficiency of anti-vascular endothelial growth factor drug switch in patients who did not respond to a series of bevacizumab injections. (PubMed, Indian J Ophthalmol) - "Switching anti-VEGF agents appears anatomically beneficial in nonresponding eyes. Notably, the inclusion of a control group continuing bevacizumab despite poor response allows for a more reliable evaluation of treatment efficacy, addressing a key limitation of prior studies and contributing to the evidence-based rationale for agent switching."

Journal • Age-related Macular Degeneration • Macular Degeneration • Macular Edema • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD (clinicaltrials.gov) - P3 | N=450 | Not yet recruiting | Sponsor: Tasly Pharmaceutical Group Co., Ltd

New P3 trial

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration (clinicaltrials.gov) - P3 | N=488 | Completed | Sponsor: Bio-Thera Solutions | Active, not recruiting ➔ Completed | Trial primary completion date: Apr 2024 ➔ Apr 2025

Trial completion • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice. (PubMed, Int J Retina Vitreous) - "The switch to faricimab in a T&E regimen significantly increased treatment intervals maintaining BCVA in patients with nAMD under other anti-VEGF treatments. No serious adverse events were reported. Longer follow-up is needed to confirm these results."

Journal • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Choroidal changes after antiVEGF in neovascular age-related macular degeneration with type 1 and 3 macular neovascularization. (PubMed, Int Ophthalmol) - "Patients with nAMD (type 1 MNV) have higher CT than patients with type 3. However, patients with type 1 MNV experience significant choroidal thinning, and CT is similar in both groups after antiVEGF treatment. Smoking, type of drusen or other OCT features have no influence in this reduction."

Journal • Retrospective data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

The Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Biosimilars in Retinopathy of Prematurity. (PubMed, Acta Paediatr) - "Biosimilar anti-vascular endothelial growth factor agents demonstrated safety and reasonable efficacy. Biosimilars are a cost-effective alternative and may improve clinical outcomes in low-income countries. Randomised controlled trials should compare biosimilars to their reference biologic."

Journal • Retinal Disorders • Retinopathy of Prematurity

Investigating Predictors of Retreatment following Initial Antivascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Systematic Review and Meta-Analysis. (PubMed, J Curr Ophthalmol) - "Among children treated with anti-VEGF agents, the highest IR occurred with intravitreal ranibizumab (IVR, 0.25 mg) (27%, 95% CI: 19%-35%) and intravitreal aflibercept (IVA, 0.4 mg) (27%, 95% CI: 6%-47%), followed by intravitreal conbercept (IVC, 0.25 mg) (16%, 95% CI: 13%-20%). The lowest IR was observed in children treated with intravitreal bevacizumab (IVB, 0.625 mg) (11%, 95% CI: 7%-14%)...While anti-VEGF therapy is effective for ROP treatment, there are significant differences in IR among different agents. IVB treatment appears to yield the most consistent results compared to other agents."

Journal • Retrospective data • Review • Retinal Disorders • Retinopathy of Prematurity

Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors (clinicaltrials.gov) - P2 | N=35 | Not yet recruiting | Sponsor: Sun Yat-sen University

New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • PD-L1

Evaluation of the Duration of Good Visual Acuity During Anti-VEGF Therapy for Age-Related Macular Degeneration in Routine Clinical Practice. (PubMed, Int J Mol Sci) - "Over nine years, 30,209 aflibercept and 10,876 ranibizumab injections were administered to 6043 patients...Furthermore, the beneficial effects of aflibercept treatment are observed with less frequent dosing. Our results suggest that using anti-VEGF compounds that target multiple domains provides a detectable advantage in treating age-related macular degeneration, particularly when these agents have a longer duration of action."

Journal • Retrospective data • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Network Meta-Analysis of Bevacizumab Gamma Versus Competing Interventions for Treating Neovascular Age-Related Macular Degeneration in the United Kingdom. (PubMed, J Mark Access Health Policy) - "The included anti-VEGF treatments were ranibizumab, aflibercept, faricimab, and bevacizumab gamma. At 12 months, all anti-VEGF treatments were similarly efficacious to ranibizumab 0.5 mg every four weeks (Q4W) in terms of CFB in BCVA, the proportion of patients gaining 15 or more letters, and the proportion of patients losing less than 15 letters (except for ranibizumab 0.5 mg every 12 weeks [Q12W] and ranibizumab 0.5 mg pro re nata [PRN]). Bevacizumab gamma provided similar improvements in visual acuity to other anti-VEGF treatments."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Predictors of persistent avascular retina in retinopathy of prematurity treated with intravitreal ranibizumab. (PubMed, J AAPOS) - "Slower RVOS, advanced ROP severity, larger ROP CCH, and later PNA at IVR were independent PAR predictors. The nomogram reliably stratified risk for post-IVR management."

Journal • Retinal Disorders • Retinopathy of Prematurity

Novel Needle for Intravitreal Injections Does Not Affect Biological Activity of Anti-VEGF Drugs. (PubMed, Clin Ophthalmol) - "Anti-VEGF drugs, such as ranibizumab, faricimab, and aflibercept, were passed twice through one of the two needle types to imitate IVI. The passage of the proteins through NDN or SHN did neither affect efficient binding to their target, nor their capacity to prevent VEGF-A165-induced barrier dysfunction. Overall, regarding the stability of therapeutic proteins, the NDN was not inferior to the SHN, and can now be considered for evaluation in clinical studies."

Journal • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology

Long-term Outcome of Anti-VEGF Treatment in Retinopathy of Prematurity: A 12-Year Follow-Up with Ultra-Widefield Imaging. (PubMed, Retin Cases Brief Rep) - "This case exemplifies the potential for long-term stabilization of ROP after anti-VEGF therapy without additional interventions uniquely supported by 12 years of UWF monitoring. Stability has so far been maintained despite the presence of peripheral avascular retina - an outcome that carries significant implications for the management of similar future cases."

Journal • Anesthesia • Ophthalmology • Respiratory Diseases • Retinal Disorders • Retinopathy of Prematurity

PAVILION: A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (clinicaltrials.gov) - P3 | N=174 | Active, not recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Jun 2025 ➔ Jan 2026

Trial completion date • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders

Significant Correlation Between Choroidal Thickness and Decrease in Choroidal Blood Flow After Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration. (PubMed, Ophthalmol Ther) - "IVBr is associated with significant reductions in CRT and SFCT and may decrease choroidal blood flow, particularly in older patients and those with thinner SFCTs."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent? (PubMed, Life (Basel)) - "The last treatment before switching was 2 mg aflibercept in 76%, faricimab in 18%, ranibizumab in 3% and bevacizumab in 3% of cases...The main reasons for switching were recalcitrant nAMD with persistent fluid despite q4w dosing (50%) or the wish for treatment extension beyond 6 weeks (32%). In the future, these data will aid in the design of prospective real-world studies comparing the efficacy of high-dose 8 mg aflibercept with older generation treatment options, especially 2 mg aflibercept."

Journal • Age-related Macular Degeneration • Hematological Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Combined retinal vein occlusion and retinal artery occlusion in a patient undergoing therapy for metastatic breast cancer: a case report. (PubMed, J Med Case Rep) - "This case report highlights the factors associated with retinal occlusion during aromatase inhibitor treatment for breast cancer, aiming to prevent ocular adverse events and visual deterioration, and underscoring the importance of ophthalmic screening for early diagnosis and appropriate treatment, as visual disturbances may be underestimated owing to the systemic pathology."

Journal • Breast Cancer • Oncology • Ophthalmology • Solid Tumor

Cost-Effectiveness of Vascular Endothelial Growth Factor Inhibitors in the Management of Wet Age-Related Macular Degeneration: A Systematic Review. (PubMed, Value Health Reg Issues) - "Decision making in wAMD treatment requires more thorough economic evaluations that incorporate standardized methodologies and lengthy cost assessments."

HEOR • Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P3 | N=561 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Adverse events • Enrollment open • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Comparative efficacy and safety of faricimab, aflibercept, conbercept, and ranibizumab for neovascular age-related macular degeneration: a systematic review and network meta-analysis. (PubMed, Eur J Pharmacol) - "Aflibercept and conbercept may be preferred when anatomical outcomes are prioritized, whereas faricimab's extended dosing interval could benefit treatment-adherent populations. The superior safety profile of aflibercept 2 mg warrants consideration in risk averse patients. These differential effects support personalized therapeutic decision-making."

Journal • Retrospective data • Review • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

M-VIVA: Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting (clinicaltrials.gov) - P=N/A | N=117 | Recruiting | Sponsor: Singapore National Eye Centre

New trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • CXCL8

AAVIATE: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: AbbVie | Trial completion date: Aug 2026 ➔ Feb 2027 | Trial primary completion date: Oct 2025 ➔ Aug 2026

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Computational modeling of anti-VEGFA drug interactions with VEGF-A: Insights into therapeutic strategies for neovascular AMD. (PubMed, Comput Biol Chem) - "In this study, we performed the first integrated in silico evaluation of six clinically relevant anti-VEGF drugs: abicipar, aflibercept, bevacizumab, brolucizumab, faricimab, and ranibizumab. This systematic analysis highlights the coexistence of evolutionary conservation and rational molecular engineering as complementary strategies shaping anti-VEGF drug performance. Overall, our findings demonstrate that computational modeling offers a cost-effective and predictive tool to guide the optimization of current therapies and the rational design of next-generation anti-VEGF agents for nAMD and other retinal vascular disorders."

Journal • Age-related Macular Degeneration • Cardiovascular • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Analysis of OCT-Based Biomarkers and Recurrence in Eyes with Diabetic Macular Edema Following Anti-VEGF Therapy. (PubMed, Int J Gen Med) - "This retrospective cohort study included 122 eyes with DME treated with anti-VEGF monotherapy (ranibizumab; Novartis Pharma Schweiz AG, Basel, Switzerland) at Pinghu First People's Hospital (January 2020 - December 2023)...HRF, SRF, and EZ integrity are key OCT biomarkers for DME recurrence. A combined model aids risk stratification for personalized management."

Biomarker • Journal • Diabetic Macular Edema • Infectious Disease • Ophthalmology

Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Carmen Clapp | Trial completion date: Jun 2026 ➔ Jun 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Breast Cancer • Diabetic Macular Edema • Diabetic Retinopathy • Ophthalmology • Retinal Disorders • PRL